Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

RCT (n=566) found neither avelumab plus pegylated liposomal doxorubicin (PLD), nor avelumab alone increased progression free survival (PFS) or overall survival (OS) vs PLD alone (PFS = 3.7, 1.9 and 3.5 months, OS = 15.7, 11.8 and 13.1 respectively).

Source:

The Lancet Oncology